--- title: 'Clinical Daily Summary: What Happened on October 30, 2026' headline: Geron ends Phase III Rytelo trial over survival outlook description: Nuvation Bio plans a European expansion of its glioma trial. Starton and Stanford will study a CAR-T combination in multiple myeloma. url: https://thebench.bio/news/clinical/2026-10-30 topic: clinical date: '2026-10-30' covers: - '2026-10-30' date_published: '2026-10-30T12:03:15Z' date_modified: '2026-10-30T12:03:15Z' tags: - Clinical - Research sources: 3 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 30, 2026 **Geron ends Phase III Rytelo trial over survival outlook** Nuvation Bio plans a European expansion of its glioma trial. Starton and Stanford will study a CAR-T combination in multiple myeloma. ## Today in brief Geron discontinued its Phase III IMpactMF trial after an independent committee concluded Rytelo was unlikely to meet the overall-survival goal. [1] ## Geron stops Rytelo trial after committee sees limited survival potential Geron stopped the Phase III IMpactMF trial of Rytelo after its independent monitoring committee judged the drug unlikely to improve overall survival enough to meet the primary endpoint. [1] The trial enrolled 327 people with myelofibrosis, and the committee found no new safety concerns in this group. [1] Geron said it will assess the results for insights relevant to future myelofibrosis research. [1] The company plans to study Rytelo with Jakafi in frontline myelofibrosis in the Phase I IMproveMF study. [1] ## Also worth knowing - Nuvation Bio plans to add trial sites in France, Germany, Italy, Spain, Sweden and the UK to its Phase III SIGMA study of safusidenib for IDH1-mutant glioma. [2] - Starton Therapeutics and Stanford School of Medicine agreed to test STAR-LLD with a CAR-T therapy in an investigator-led study of relapsed or refractory multiple myeloma. [3] ## The day in numbers - **327**: People enrolled in Geron's discontinued Phase III IMpactMF trial. [1] ## Also published - [What Needs to Happen Beyond the Clinical Trial Modernization Act](), Applied Clinical Trials - [Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica](), Pharmaceutical Executive - [ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance](), Applied Clinical Trials - [Closing the Pediatric Evidence Gap](), Pharmaceutical Executive - [How Embedding Research Into Routine Community Care Changes Who Gets Access](), Applied Clinical Trials - [How Preventative Medications May Impact the Lingering Impact of COVID-19](), Pharmaceutical Executive ## Sources 1. [Geron winds down Phase III rare blood cancer trial after muted efficacy ](), Clinical Trials Arena, 2026-10-30 2. [Nuvation Bio to broaden Phase III glioma trial into Europe](), Clinical Trials Arena, 2026-10-30 3. [Starton and Stanford to study STAR-LLD combination in MM](), Clinical Trials Arena, 2026-10-30 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: